OR WAIT null SECS
A form of testosterone replacement therapy that uses implantable testosterone pellets (Testopel) is a viable alternative to existing treatments for hypogonadism, with a number of practical advantages for patients.
San Diego-A form of testosterone replacement therapy that uses implantable testosterone pellets (Testopel) is a viable alternative to existing treatments for hypogonadism, with a number of practical advantages for patients, investigators reported at the Sexual Medicine Society of North America 2009 annual meeting.
The pellets have been found to provide sustained levels of testosterone for at least 4 months, decrease gonadotropin levels, and are well tolerated. But for Andrew McCullough, MD, their real attraction is pragmatic.
"It came to me as I was flossing my teeth in preparation for my dental appointment," said Dr. McCullough, associate professor of urology at the New York University School of Medicine. "Had I been flossing as I was supposed to for the last 3 months, or was I doing what everyone else does and flossing before the appointment so I could tell him that I floss regularly?"
Compliance levels in testosterone gel studies tend to be artificially high, Dr. McCullough noted. In real life, men are much less likely to comply with the daily application of gel needed to maintain testosterone levels.
Thus, implantable pellets may be more feasible for large numbers of men, according to Dr. McCullough. He and colleagues reviewed data on 172 patients with 240 implantations of Testopel pellets. Sixty of those patients had two or more implantations.
The researchers obtained 354 follow-up levels an average of 77 days following implantation. Mean age in the cohort was 60 years. About 16% of subjects received six or seven pellets, 43% received eight or nine pellets, and 41% received 10 to 12 pellets.
Pellets effective up to 4 months
The pellets were found to raise testosterone levels for at least 4 months, with those receiving 10 to 12 pellets enjoying the best results.
"We're trying to refine the number of pellets based on patients' body mass index and aromatase activity," said Dr. McCullough. "For now, the standard I use is 10 pellets."
In a separate, 32-patient retrospective study, Dr. McCullough's team observed gonadotropin levels decreasing as testosterone levels rose following pellet implantation. The researchers also suggested that serum gonadotropin levels may be combined with serum testosterone levels to determine optimal timing for re-implantation.
When Dr. McCullough first presented his data at an AUA section meeting, he was asked whether he starts his patients on testosterone gels first.
"I told them, no, I don't," he said. "I want the man to know how it feels to have a normal testosterone level. When he comes back in 3 months, he can then tell me which therapeutic option, if any, he wants. What we'll know at that point is if low testosterone was the cause of his symptoms. If he has not symptomatically improved, replacing his testosterone is not the solution.
"Testosterone replacement is a lifetime thing, so it makes sense to know definitively at the outset whether replacement is the right thing for him."